Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

3 months ago 13

1. Homepage
2. Finance
3. Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say